Megexia

Megestrol acetate, the active ingredient in Megexia, is a progestogen presented as a tablet for oral use. It stimulates appetite and possesses antineoplastic activity, making it useful in the management of cancer‑related cachexia, advanced breast cancer, endometrial cancer, and hormone therapy for endometrial hyperplasia.

GNH USA supplies Megexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU GMP standards and offering reliable global distribution. The product is manufactured under strict quality controls to meet international regulatory requirements.

Megexia (megestrol acetate) acts on hormonal pathways and is indicated for the following conditions:

- Cachexia (AIDS or cancer): improves appetite and promotes weight gain in affected patients. - Advanced breast cancer: provides antineoplastic effect and may reduce tumor progression. - Endometrial cancer: used as hormonal therapy to inhibit tumor growth. - Endometrial hyperplasia: administered to control abnormal endometrial proliferation.

Megexia may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Vomiting - Weight gain - Edema - Fatigue - Menstrual irregularities

Serious or Rare Side Effects: - Thromboembolic events - Adrenal suppression - Severe allergic reaction (anaphylaxis) - Hyperglycemia or new‑onset diabetes - Cushingoid syndrome

Before initiating Megexia, clinicians should consider several safety measures.

- Assess nutritional status: monitor weight and appetite regularly. - Screen for thromboembolic risk: evaluate history of clotting disorders. - Monitor blood glucose: watch for hyperglycemia, especially in diabetic patients. - Evaluate adrenal function: consider cortisol levels during prolonged therapy. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Megexia can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations of megestrol acetate. - Anticoagulants (e.g., warfarin): may enhance bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness. - Diabetes medications: hyperglycemic effect of megestrol may require dose adjustment. - Hormonal contraceptives: may decrease contraceptive efficacy.